Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANT (Cerebral Hemorrhage And NXY Treatment)
2004-000566-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of OKN-007 in intracerebral hemorrhage (ICH) (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Started Aug 2004; status: completed.
02
Drugs
OKN-007
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on 2004-000566-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000566-12.